{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:13:01Z","timestamp":1776867181652,"version":"3.51.2"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jtct.2025.04.005","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:25:28Z","timestamp":1744151128000},"page":"436-447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9863-8464","authenticated-orcid":false,"given":"Mitchell E.","family":"Horwitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-3467","authenticated-orcid":false,"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie B.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-7099","authenticated-orcid":false,"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uri","family":"Goshen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Schwarzbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roei D.","family":"Mazor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Stiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jtct.2025.04.005_bib0001","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.04.005_bib0002","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.04.005_bib0003","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40291-023-00662-1","article-title":"Omidubicel: first approval","volume":"27","author":"Heo","year":"2023","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.04.005_bib0004","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.exphem.2011.12.005","article-title":"Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment","volume":"40","author":"Peled","year":"2012","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.04.005_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1200\/JCO.18.00053","article-title":"Phase I\/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide","volume":"37","author":"Horwitz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.04.005_bib0006","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1172\/JCI74556","article-title":"Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment","volume":"124","author":"Horwitz","year":"2014","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.jtct.2025.04.005_bib0007","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.2021011719","article-title":"Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.04.005_bib0008","article-title":"Immune reconstitution profiling suggests antiviral protection after transplantation with omidubicel: a phase 3 substudy","volume":"29","author":"Szabolcs","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2025.04.005_bib0009","doi-asserted-by":"crossref","first-page":"338.e1","DOI":"10.1016\/j.jtct.2023.01.031","article-title":"Multicenter long-term follow-up of allogeneic hematopoietic cell transplantation with omidubicel: a pooled analysis of five prospective clinical trials","volume":"29","author":"Lin","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2025.04.005_bib0010","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jtct.2023.06.009","article-title":"Corrigendum to 'multicenter long-term follow-up of allogeneic hematopoietic cell transplantation with omidubicel: a pooled analysis of five prospective clinical trials","volume":"30","author":"Lin","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.jtct.2025.04.005_bib0011","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1182\/bloodadvances.2020003371","article-title":"High progression-free survival after intermediate intensity double unit cord blood transplantation in adults","volume":"4","author":"Barker","year":"2020","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.jtct.2025.04.005_bib0012","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jtct.2025.04.005_bib0013","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program\u2013sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.04.005_bib0014","doi-asserted-by":"crossref","unstructured":"Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med.375(10):944-953.","DOI":"10.1056\/NEJMoa1602074"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725011388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725011388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:02:04Z","timestamp":1762639324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725011388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2666636725011388"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.04.005","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}